Achillion Pharmaceuticals, Inc.

( )
ACHN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 6.56%74.701.0%$1317.97m
BIIBBiogen, Inc. 1.03%327.451.5%$652.73m
AMGNAmgen, Inc. 1.98%214.541.3%$528.56m
REGNRegeneron Pharmaceuticals, Inc. 3.52%457.922.6%$493.97m
ILMNIllumina, Inc. 1.76%274.703.5%$395.63m
VRTXVertex Pharmaceuticals, Inc. 0.89%232.041.9%$340.69m
MRNAModerna, Inc. 22.73%29.160.0%$244.82m
ALXNAlexion Pharmaceuticals, Inc. -1.42%94.782.0%$216.14m
AAgilent Technologies, Inc. 0.22%78.121.6%$163.65m
EXASEXACT Sciences Corp. -6.67%80.7624.0%$139.73m
INCYIncyte Corp. 0.84%77.972.5%$113.49m
BMRNBioMarin Pharmaceutical, Inc. 0.24%91.224.3%$106.57m
SGENSeattle Genetics, Inc. -0.24%112.116.1%$105.02m
CODXCo-Diagnostics, Inc. 106.26%8.900.0%$96.40m
XLRNAcceleron Pharma, Inc. -0.94%87.366.1%$84.00m

Company Profile

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.